BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jacquelot N, Seillet C, Wang M, Pizzolla A, Liao Y, Hediyeh-Zadeh S, Grisaru-Tal S, Louis C, Huang Q, Schreuder J, Souza-Fonseca-Guimaraes F, de Graaf CA, Thia K, Macdonald S, Camilleri M, Luong K, Zhang S, Chopin M, Molden-Hauer T, Nutt SL, Umansky V, Ciric B, Groom JR, Foster PS, Hansbro PM, McKenzie ANJ, Gray DHD, Behren A, Cebon J, Vivier E, Wicks IP, Trapani JA, Munitz A, Davis MJ, Shi W, Neeson PJ, Belz GT. Blockade of the co-inhibitory molecule PD-1 unleashes ILC2-dependent antitumor immunity in melanoma. Nat Immunol 2021;22:851-64. [PMID: 34099918 DOI: 10.1038/s41590-021-00943-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Grisaru-Tal S, Rothenberg ME, Munitz A. Eosinophil-lymphocyte interactions in the tumor microenvironment and cancer immunotherapy. Nat Immunol 2022. [PMID: 36002647 DOI: 10.1038/s41590-022-01291-2] [Reference Citation Analysis]
2 Warner K, Ghaedi M, Chung DC, Jacquelot N, Ohashi PS. Innate lymphoid cells in early tumor development. Front Immunol 2022;13:948358. [DOI: 10.3389/fimmu.2022.948358] [Reference Citation Analysis]
3 Attrill GH, Lee H, Tasker AT, Adegoke NA, Ferguson AL, da Silva IP, Saw RPM, Thompson JF, Palendira U, Long GV, Ferguson PM, Scolyer RA, Wilmott JS. Detailed spatial immunophenotyping of primary melanomas reveals immune cell subpopulations associated with patient outcome. Front Immunol 2022;13:979993. [DOI: 10.3389/fimmu.2022.979993] [Reference Citation Analysis]
4 Wagner M, Koyasu S. Cancer immunosurveillance by ILC2s. Trends Cancer 2022:S2405-8033(22)00150-9. [PMID: 35871054 DOI: 10.1016/j.trecan.2022.06.010] [Reference Citation Analysis]
5 Kumar A, Taghi Khani A, Sanchez Ortiz A, Swaminathan S. GM-CSF: A Double-Edged Sword in Cancer Immunotherapy. Front Immunol 2022;13:901277. [DOI: 10.3389/fimmu.2022.901277] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Ito A, Akama Y, Satoh-takayama N, Saito K, Kato T, Kawamoto E, Gaowa A, Park EJ, Takao M, Shimaoka M. Possible Metastatic Stage-Dependent ILC2 Activation Induces Differential Functions of MDSCs through IL-13/IL-13Rα1 Signaling during the Progression of Breast Cancer Lung Metastasis. Cancers 2022;14:3267. [DOI: 10.3390/cancers14133267] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ikutani M, Nakae S. Heterogeneity of Group 2 Innate Lymphoid Cells Defines Their Pleiotropic Roles in Cancer, Obesity, and Cardiovascular Diseases. Front Immunol 2022;13:939378. [DOI: 10.3389/fimmu.2022.939378] [Reference Citation Analysis]
8 Yin G, Zhao C, Pei W. Crosstalk between macrophages and innate lymphoid cells (ILCs) in diseases. Int Immunopharmacol 2022;110:108937. [PMID: 35779490 DOI: 10.1016/j.intimp.2022.108937] [Reference Citation Analysis]
9 Cederberg RA, Franks SE, Wadsworth BJ, So A, Decotret LR, Hall MG, Shi R, Hughes MR, McNagny KM, Bennewith KL. Eosinophils Decrease Pulmonary Metastatic Mammary Tumor Growth. Front Oncol 2022;12:841921. [PMID: 35756626 DOI: 10.3389/fonc.2022.841921] [Reference Citation Analysis]
10 Wu L, Zhao W, Tang S, Chen R, Ji M, Yang X. Role of ILC2s in Solid Tumors: Facilitate or Inhibit? Front Immunol 2022;13:886045. [DOI: 10.3389/fimmu.2022.886045] [Reference Citation Analysis]
11 Zebboudj A, Amisaki M, Balachandran VP. ILC2s-Bipartisan politicians in cancer. Sci Immunol 2022;7:eabq2791. [PMID: 35658014 DOI: 10.1126/sciimmunol.abq2791] [Reference Citation Analysis]
12 Jou E, Rodriguez-Rodriguez N, Ferreira AF, Jolin HE, Clark PA, Sawmynaden K, Ko M, Murphy JE, Mannion J, Ward C, Matthews DJ, Buczacki SJA, McKenzie ANJ. An innate IL-25-ILC2-MDSC axis creates a cancer-permissive microenvironment for Apc mutation-driven intestinal tumorigenesis. Sci Immunol 2022;7:eabn0175. [PMID: 35658010 DOI: 10.1126/sciimmunol.abn0175] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
13 Nong C, Guan P, Li L, Zhang H, Hu H. Tumor immunotherapy: Mechanisms and clinical applications. MedComm – Oncology 2022;1. [DOI: 10.1002/mog2.8] [Reference Citation Analysis]
14 Rosalia B, Matteo B, Ester B, Giovanni Z, Daniela Claudia M, Pier Giulio C, Giuseppe E, Angela I. Tissue-Resident Innate Immune Cell-Based Therapy: A Cornerstone of Immunotherapy Strategies for Cancer Treatment. Front Cell Dev Biol 2022;10:907572. [DOI: 10.3389/fcell.2022.907572] [Reference Citation Analysis]
15 Mi L, Guo W, Xu Z. Crosstalk between ILC2s and Th2 CD4+ T Cells in Lung Disease. Journal of Immunology Research 2022;2022:1-12. [DOI: 10.1155/2022/8871037] [Reference Citation Analysis]
16 Chung DC, Jacquelot N, Ghaedi M, Warner K, Ohashi PS. Innate Lymphoid Cells: Role in Immune Regulation and Cancer. Cancers 2022;14:2071. [DOI: 10.3390/cancers14092071] [Reference Citation Analysis]
17 Korangy F, Heinrich B, Greten TF. Innate lymphoid cells at the crossroads of innate and adaptive immunity. Hepatology 2022. [PMID: 35366023 DOI: 10.1002/hep.32502] [Reference Citation Analysis]
18 Spits H, Mjösberg J. Heterogeneity of type 2 innate lymphoid cells. Nat Rev Immunol 2022. [PMID: 35354980 DOI: 10.1038/s41577-022-00704-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
19 Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors-More than Boosting T-Cell Responses? Cancers (Basel) 2022;14:1710. [PMID: 35406483 DOI: 10.3390/cancers14071710] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Jacquelot N, Seillet C, Vivier E, Belz GT. Innate lymphoid cells and cancer. Nat Immunol 2022. [PMID: 35228695 DOI: 10.1038/s41590-022-01127-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 9.0] [Reference Citation Analysis]
21 Park JH, Lee HK. Current Understanding of Hypoxia in Glioblastoma Multiforme and Its Response to Immunotherapy. Cancers (Basel) 2022;14:1176. [PMID: 35267480 DOI: 10.3390/cancers14051176] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ricardo-Gonzalez RR, Molofsky AB, Locksley RM. ILC2s - development, divergence, dispersal. Curr Opin Immunol 2022;75:102168. [PMID: 35176675 DOI: 10.1016/j.coi.2022.102168] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
23 Dean JW, Zhou L. Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity. Trends in Immunology 2022. [DOI: 10.1016/j.it.2022.01.008] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Cristiani CM, Capone M, Garofalo C, Madonna G, Mallardo D, Tuffanelli M, Vanella V, Greco M, Foti DP, Viglietto G, Ascierto PA, Spits H, Carbone E. Altered Frequencies and Functions of Innate Lymphoid Cells in Melanoma Patients Are Modulated by Immune Checkpoints Inhibitors. Front Immunol 2022;13:811131. [DOI: 10.3389/fimmu.2022.811131] [Reference Citation Analysis]
25 Jacquelot N, Ghaedi M, Warner K, Chung DC, Crome SQ, Ohashi PS. Immune Checkpoints and Innate Lymphoid Cells-New Avenues for Cancer Immunotherapy. Cancers (Basel) 2021;13:5967. [PMID: 34885076 DOI: 10.3390/cancers13235967] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
26 Newnes HV, Armitage JD, Audsley KM, Bosco A, Waithman J. Directing the Future Breakthroughs in Immunotherapy: The Importance of a Holistic Approach to the Tumour Microenvironment. Cancers (Basel) 2021;13:5911. [PMID: 34885021 DOI: 10.3390/cancers13235911] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Appleton E, Hassan J, Chan Wah Hak C, Sivamanoharan N, Wilkins A, Samson A, Ono M, Harrington KJ, Melcher A, Wennerberg E. Kickstarting Immunity in Cold Tumours: Localised Tumour Therapy Combinations With Immune Checkpoint Blockade. Front Immunol 2021;12:754436. [PMID: 34733287 DOI: 10.3389/fimmu.2021.754436] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
28 Wagner M, Koyasu S. Innate Lymphoid Cells in Skin Homeostasis and Malignancy. Front Immunol 2021;12:758522. [PMID: 34691082 DOI: 10.3389/fimmu.2021.758522] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
29 Walton K, Walker K, Riddle M, Koehn BH, Reff J, Sagatys EM, Linden MA, Pidala J, Kim J, Lee MC, Kiluk JV, Hui JYC, Yun SY, Xing Y, Stefanski H, Lawrence HR, Lawrence NJ, Tolar J, Anasetti C, Blazar BR, Sebti SM, Betts BC. Dual JAK2/Aurora kinase A inhibition prevents human skin graft rejection by allo-inactivation and ILC2-mediated tissue repair. Am J Transplant 2021. [PMID: 34668635 DOI: 10.1111/ajt.16870] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
30 Roma S, Carpen L, Raveane A, Bertolini F. The Dual Role of Innate Lymphoid and Natural Killer Cells in Cancer. from Phenotype to Single-Cell Transcriptomics, Functions and Clinical Uses. Cancers (Basel) 2021;13:5042. [PMID: 34680190 DOI: 10.3390/cancers13205042] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
31 Poncin A, Onesti CE, Josse C, Boulet D, Thiry J, Bours V, Jerusalem G. Immunity and Breast Cancer: Focus on Eosinophils. Biomedicines 2021;9:1087. [PMID: 34572273 DOI: 10.3390/biomedicines9091087] [Reference Citation Analysis]
32 Bruchard M, Ghiringhelli F. ILC2s in cancer: context matters. Nat Immunol 2021;22:804-6. [PMID: 34099921 DOI: 10.1038/s41590-021-00945-x] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
33 Dhir A, Pillai A. The innate power of PD-1 blockade. Sci Immunol 2021;6:eabl6919. [DOI: 10.1126/sciimmunol.abl6919] [Reference Citation Analysis]
34 Mattiola I, Mantovani A, Locati M. The tetraspan MS4A family in homeostasis, immunity, and disease. Trends Immunol 2021;42:764-81. [PMID: 34384709 DOI: 10.1016/j.it.2021.07.002] [Reference Citation Analysis]
35 Jacquelot N, Belz GT. Type 2 innate lymphoid cells: a novel actor in anti-melanoma immunity. Oncoimmunology 2021;10:1943168. [PMID: 34239775 DOI: 10.1080/2162402X.2021.1943168] [Cited by in F6Publishing: 1] [Reference Citation Analysis]